Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Anti-CD30 chimeric antigen receptor T cell therapy - Immune cell

Drug Profile

Anti-CD30 chimeric antigen receptor T cell therapy - Immune cell

Alternative Names: Anti-CD30 CART cell therapy - Immune Cell; Anti-CD30 CART cells - Immune cell; ICAR30 CAR-T cells - Immune Cell

Latest Information Update: 05 Jan 2018

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Immune Cell
  • Developer Immune Cell; Weifang People's Hospital
  • Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
  • Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Anaplastic large cell lymphoma; Hodgkin's disease

Most Recent Events

  • 01 Mar 2017 Phase-I clinical trials in Anaplastic large cell lymphoma (In adults, In children, In the elderly, In adolescents) in China (IV) (NCT03383965)
  • 01 Mar 2017 Phase-I clinical trials in Hodgkin's disease (In adults, In adolescents, In children, In the elderly) in China (IV) (NCT03383965)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top